Applications of 4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Benzoic Acid in Industrial Manufacturing

4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Benzoic Acid serves as a critical intermediate in the synthesis of pharmaceutical actives, targeted anti-tumor agents, advanced agrochemicals, laboratory reference compounds, and kinase inhibitor research materials. We manufacture this compound with consistent purity and supply, supporting diverse downstream integration in highly regulated sectors.

1. Pharmaceutical Drug Intermediate for Protein Kinase Inhibitors

This material functions as a core building block in the synthesis of tyrosine kinase inhibitors, particularly for oncological therapies targeting chronic myeloid leukemia and certain non-small cell lung cancer indications. Our partners integrate it into multi-step API syntheses, applying stringent in-process controls to ensure regulatory acceptance and reproducible yields.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia monographs for intermediates (Ph. Eur.)
• 21 CFR 210/211 US FDA cGMP regulations
• Chinese Pharmacopoeia (ChP) guidance for chemical intermediates

Typical usage ratio

• 5-15% w/w relative to total weight of synthesis batch, adjusted by final API target and route efficiency

Downstream process integration

• Introduced after initial pyrimidine coupling, followed by amide bond construction and protective group removals in multi-step processes

Final product types

• Imatinib mesylate (oncology API)
• Nilotinib (oncology API)
• Research-grade kinase inhibitor analogues

2. Reference Standard and Analytical Sample Preparation

High-purity batches are designated for the production of analytical reference standards, allowing downstream users in analytical laboratories to validate HPLC, LC-MS/MS, and NMR quantification methods. These standards play a critical role in API batch release, stability studies, and impurity profiling under regulated testing regimes.

Industry compliance standards

• USP and EP reference standard guidelines
• ISO/IEC 17025 requirements for calibration and testing laboratories
• GLP (Good Laboratory Practice) for pharmaceutical analysis

Typical usage ratio

• 0.2–2 mg per individual analysis, standardized in line with analytical method sensitivity

Downstream process integration

• Dissolved into validated solvents as calibration stock solutions, used during pharmaceutical quality control and impurity tracking

Final product types

• Certified analytical reference vials
• Calibration solutions and mixtures for pharmaceutical QC
• HPLC/UPLC marker substances for stability studies

3. Precursor in Agrochemical Active Ingredient Development

The compound offers a modular scaffold for the molecular design of pyrimidine-based agrochemicals, especially in the creation of novel herbicidal or fungicidal actives with pyridinyl and benzoic acid motifs. Agrochemical R&D employs it for targeted synthetic modifications optimizing bioactivity and selectivity profiles.

Industry compliance standards

• OECD Principles of Good Laboratory Practice
• FAO/WHO Technical Guidelines for pesticide synthesis intermediates
• REACH (EC No 1907/2006) Intermediate Registration

Typical usage ratio

• 3–10% w/w in initial synthetic screening; scale-ups may adjust by reaction optimization findings

Downstream process integration

• Employed after pyridinyl derivatization during lead optimization and library expansion phases in agrochemical discovery

Final product types

• Pyridinyl-pyrimidine herbicidal leads
• Experimental fungicidal actives
• Intermediate scaffolds for crop protection formulation

4. Discovery Chemistry for Structure-Activity Relationship (SAR) Studies

As a high-purity scaffold, the material supports medicinal chemistry labs in synthesizing focused libraries for SAR work, particularly among kinase inhibition and cell signaling research portfolios. Chemists use it for structural diversification, investigating substituent effects on receptor binding and in vitro potency.

Industry compliance standards

• Institutional GLP standards for medicinal chemistry infrastructure
• Synthetic chemistry documentation per ACS and RSC publication standards

Typical usage ratio

• 0.5–2 mmol per reaction, tailored based on parallel synthesis array size and available analytical throughput

Downstream process integration

• Introduced in early route scouting and lead elaboration to enable rapid analog evaluation in micro-scale reactions

Final product types

• SAR compound arrays
• Biological evaluation candidates for cell assays
• Kinase pathway selective probes

5. Custom Synthesis for Academic and Contract Research Organizations

Specialty research and contract labs source this compound as a foundation for the generation of new molecular probes, chemical biology tools, and exploratory kinase inhibitors for non-commercial research. Custom projects utilize our substance at the request of principal investigators or project leads, often requiring specific documentation and analytical certification upon delivery.

Industry compliance standards

• Research Use Only (RUO) labeling and disclosure per local academic requirements
• Institution-specific chemical safety protocols (including MSDS provision)
• Material transfer agreement (MTA) documentation

Typical usage ratio

• 10 mg to 10 g per order, scaled for individual research campaign duration

Downstream process integration

• Distributed as solid or solution, with batch-specific COA and spectral data, ready for further functionalization or biological evaluation

Final product types

• Molecular probes for cellular signaling studies
• Custom kinase pathway inhibitors in research pipelines
• Academic project-specific intermediates

6. Impurity Marker for Regulatory Toxicological Profiling

In regulated pharmaceutical synthesis, this compound occasionally serves as an impurity marker to establish toxicological thresholds for process intermediates. Downstream QA and regulatory teams spike or compare process samples to evaluate synthetic route cleanliness, reporting to support regulatory filings and manufacturing change controls.

Industry compliance standards

• ICH Q3A(R2) Guidelines for Impurities in New Drug Substances
• FDA Guidance for Industry: Control of Impurities in Drug Substances
• EMA Impurity Testing Requirements

Typical usage ratio

• ≤ 0.1% total batch weight; often introduced as spiking standards at 10–100 ppm for validated method calibration

Downstream process integration

• Added to analytical runs during batch release and stability testing to confirm impurity identification and quantify clearance by downstream purification

Final product types

• Regulatory submission packages (impurity sections)
• Batch release analytical reports
• GMP process validation files